2471 results about "Isopropyl" patented technology

The present invention relates to a catalyst composition for ethylene oligomerization and the use thereof. Such catalyst composition includes chromium compound, ligand containing P and N, activator and accelerator; wherein the chromium compound is selected from the group consisting of acetyl acetone chromium, THF-chromium chloride and Cr(2-ethylhecanoate)3; general formula of the ligand containing P and N is shown as:in which R1, R2, R3 and R4 are phenyl, benzyl, or naphthyl. R5 is isopropyl, butyl, cyclopropyl, cyclopentyl, cyclohexyl or fluorenyl; the activatior is methyl aluminoxane, ethyl aluminoxane, propyl aluminoxane and / or butyl aluminoxane; the accelerator is selected from the group consisting of 1,1,2,2,-tetrachloroethane, 1,1,2,2-tetrabromoethane, 1,1,2,2-tetrafluoroethane, and compounds having a formula of X1R6X2, in which X1 and X2 are F, Cl, Br, I or alkoxyl, R6 is alkylene or arylene group; the molar ratio of chromium compound, ligand containing P and N, activator and accelerator is 1:0.5˜10:50˜3000:0.5˜10. After mixing the four components mentioned previously under nitrogen atmosphere for 10 minutes, they are incorporated to the reactor, or these four components are incorporated directly into the reactor. Then ethylene is introduced for oligomerization. Such catalyst can be used in producing 1-octene through ethylene oligomerization. It is advantageous in high catalysing activity, high 1-octene selectivity, etc. The catalytic activity is more than 1.0×106 g product·ma−1 Cr·h−1, the fraction of C8 linear α-olefin is more than 70% by mass.

A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits high therapeutic or prophylactic effects.

The invention relates to a preparation method of a semi-interpenetrating network nanocomposite hydrogel which can respond to variations in temperature, pH and ultraviolet to realize volume transition. The preparation method of the gel is as follows: taking temperature-sensitive monomers, namely N-isopropylacrylamide and azo type water soluble monomers, namely 4-((4-acryloxy) phenyl azo) benzoic acid as copolymerization monomers, taking modified nano-clay as a cross-linking agent, dissolving the monomers and the cross-linking agent in a cellulose type macromolecular water solution, uniformly stirring, and then performing oxidation, reduction and catalytic free radical polymerization in an ice bath under the protection of nitrogen for preparation. The gel uses nano-laponite cross-linked monomers to constitute a framework of the gel and takes cellulose type macromolecules as semi-interpenetrating macromolecules. The obtained hydrogel has the advantages of excellent mechanical properties, high swelling rate and fast and controllable stimulus response. The gel has the potential to be applied to the field of sustained release of medicaments.